Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora Sells 23,124 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CFO Michael Secora sold 23,124 shares of the company’s stock in a transaction that occurred on Wednesday, April 17th. The stock was sold at an average price of $7.58, for a total transaction of $175,279.92. Following the completion of the transaction, the chief financial officer now owns 1,231,055 shares in the company, valued at $9,331,396.90. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Michael Secora also recently made the following trade(s):

• On Wednesday, March 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $11.03, for a total transaction of $275,750.00.
• On Tuesday, February 13th, Michael Secora sold 25,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $9.86, for a total transaction of $246,500.00.

Recursion Pharmaceuticals Trading Down 0.9 %

Shares of NASDAQ RXRX opened at $7.40 on Friday. Recursion Pharmaceuticals, Inc. has a one year low of $4.54 and a one year high of $16.75. The firm’s 50 day simple moving average is $10.79 and its two-hundred day simple moving average is $9.09.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its quarterly earnings data on Tuesday, February 27th. The company reported ($0.40) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.46) by $0.06. The firm had revenue of $10.89 million during the quarter, compared to analyst estimates of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. On average, equities analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Institutional Trading of Recursion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in RXRX. ARK Investment Management LLC boosted its stake in shares of Recursion Pharmaceuticals by 200.4% during the fourth quarter. ARK Investment Management LLC now owns 20,654,287 shares of the company’s stock valued at $203,651,000 after purchasing an additional 13,777,689 shares during the period. Mubadala Investment Co PJSC purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $128,041,000. Nvidia Corp purchased a new stake in shares of Recursion Pharmaceuticals during the fourth quarter valued at approximately $75,985,000. FMR LLC lifted its stake in Recursion Pharmaceuticals by 134.4% in the third quarter. FMR LLC now owns 10,689,532 shares of the company’s stock worth $81,775,000 after acquiring an additional 6,129,935 shares during the period. Finally, Nikko Asset Management Americas Inc. lifted its stake in Recursion Pharmaceuticals by 161.2% in the fourth quarter. Nikko Asset Management Americas Inc. now owns 9,203,780 shares of the company’s stock worth $90,565,000 after acquiring an additional 5,680,656 shares during the period. Hedge funds and other institutional investors own 89.06% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on RXRX shares. TD Cowen started coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They issued a “market perform” rating on the stock. KeyCorp upped their price objective on shares of Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research report on Monday, March 4th. Finally, Needham & Company LLC restated a “buy” rating and issued a $17.00 price objective on shares of Recursion Pharmaceuticals in a research report on Tuesday, April 9th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, Recursion Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $12.75.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.